Lilly’s announces EBGLYSS provides sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

Lilly announces that more than 80 per cent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to EBGLYSY treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing.

EBGLYSS is an interleukin-13 inhibitor that selectively blocks IL-13 signaling with high binding affinity. The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.

“The chronic and persistent signs and symptoms of atopic dermatitis affect patients’ daily lives, highlighting the need for a treatment that can provide sustained, long-term relief,” said Eric Simpson, M.D., M.C.R., professor of dermatology and director of clinical research at Oregon Health & Science University School of Medicine in Portland, Oregon, and senior author and investigator of the ADjoin analysis. “These three-year results provide compelling evidence of durable efficacy and a consistent safety profile, offering further long-term evidence for health care providers seeking a new biologic treatment option for their patients.”

• 84 percent of these patients taking EBGLYSS once monthly and 83 percent taking EBGLYSS every two weeks maintained clear or almost-clear skin at three years.
• 87 percent of these patients taking EBGLYSS once monthly and 79 percent taking EBGLYSS every two weeks achieved or maintained at least 90 percent improvement in disease extent and severity at three years.
• 83 percent of these patients taking EBGLYSS once monthly and 91 percent taking EBGLYSS every two weeks did not require either high-potency topical corticosteroids or systemic treatments.

This safety profile was consistent with previous EBGLYSS studies, and no new safety signals were observed up to three years of treatment. The majority of adverse events were mild or moderate. Less than three percent of patients experienced adverse events leading to treatment discontinuation. The most common side effects of EBGLYSS were conjunctivitis, injection site reactions and shingles.

“Without adequate treatment, atopic dermatitis can leave people struggling with uncontrolled symptoms,” said Mark Genovese, M.D., senior vice president of Immunology Development at Lilly. “EBGLYSS selectively targets IL-13, one of the main drivers of inflammation in eczema. These three-year data demonstrate that EBGLYSS given once monthly provides durable symptom relief for patients who need it most.”

“These latest clinical data for EBGLYSS show the potential of this innovative medicine to provide sustained improvement of moderate-to-severe atopic dermatitis, a chronic and often debilitating condition,” said Volker Koscielny, M.D., Chief Medical Officer at Almirall. “The data can help inform clinical decision-making and are reassuring, as they show that the vast majority of patients who respond to the treatment will continue to respond over time.”

---

---

Related Topics and Keywords

ebglyss, Lilly, moderate-to-severe atopic dermatitis